BiotechTube

Camrelizumab + Apatinib + Nab-paclitaxel + Epirubicin + Cyclophosphamide

Phase 2Recruiting
1 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Triple Negative Breast Cancer

Conditions

Triple Negative Breast Cancer

Trial Timeline

Nov 1, 2022 → Dec 31, 2026

NCT ID
NCT05447702

About Camrelizumab + Apatinib + Nab-paclitaxel + Epirubicin + Cyclophosphamide

Camrelizumab + Apatinib + Nab-paclitaxel + Epirubicin + Cyclophosphamide is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Triple Negative Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05447702. Target conditions include Triple Negative Breast Cancer.

What happened to similar drugs?

1 of 20 similar drugs in Triple Negative Breast Cancer were approved

Approved (1) Terminated (1) Active (18)
✅Taxane and Carboplatin + Short-term SintilimabInnovent BiologicsApproved
🔄Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
🔄Cyclophosphamide + Placebo + Doxorubicin + Paclitaxel + Carboplatin + Veliparib + PlaceboAbbViePhase 3
🔄Capivasertib + Paclitaxel + PlaceboAstraZenecaPhase 3
🔄Sacituzumab Govitecan-hziy + Pembrolizumab + Paclitaxel + nab-Paclitaxel + Gemcitabine + CarboplatinMerckPhase 3
🔄Pembrolizumab + Sacituzumab tirumotecan + CapecitabineMerckPhase 3
🔄pembrolizumab + capecitabine + eribulin + gemcitabine + vinorelbineMerckPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05447702Phase 2Recruiting

Competing Products

20 competing products in Triple Negative Breast Cancer

See all competitors
ProductCompanyStageHype Score
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
23
eFT508eFFECTOR TherapeuticsPhase 2
17
No drugDaiichi SankyoPre-clinical
30
Tivozanib Hydrochloride + paclitaxel + PlaceboAstellas PharmaPhase 2
27
EnzalutamideAstellas PharmaPhase 2
35
Abemaciclib + BicalutamideEli LillyPhase 2
42
Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
40
Camrelizumab + Nab-Paclitaxel + CarboplatinJiangsu Hengrui MedicinePhase 2/3
34
Fluzoparib+Paclitaxel + Epirubicin+CyclophosphamideJiangsu Hengrui MedicinePhase 2
42
Camrelizumab + Nab paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
31
SHR-1210 + Apatinib +FluzoparibJiangsu Hengrui MedicinePhase 1
29
Cyclophosphamide + Placebo + Doxorubicin + Paclitaxel + Carboplatin + Veliparib + PlaceboAbbViePhase 3
40
Combination of Veliparib + LapatinibAbbViePre-clinical
26
Capivasertib + ItraconazoleAstraZenecaPhase 1
29
Datopotamab Deruxtecan (Dato-DXd) + DurvalumabAstraZenecaPhase 2
42
Paclitaxel + Carboplatin + MEDI4736 + MEDI9447AstraZenecaPhase 1/2
36
KU-0059436 (AZD2281)(PARP inhibitor) + Carboplatin + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + CarboplatinAstraZenecaPhase 1
29
Capivasertib + Paclitaxel + PlaceboAstraZenecaPhase 3
44
Olaparib Oral Product + Olaparib Oral Product in combination with DurvalumabAstraZenecaPhase 2
35
Durvalumab + Capivasertib + Oleclumab + Paclitaxel + Trastuzumab deruxtecan + Datopotamab deruxtecanAstraZenecaPhase 1/2
36